171 related articles for article (PubMed ID: 30628981)
1. Serum Calprotectin in Adolescents With Inflammatory Bowel Disease-A Pilot Investigation.
Carlsen K; Malham M; Hansen LF; Petersen JJH; Paerregaard A; Houen G; Wewer V
J Pediatr Gastroenterol Nutr; 2019 May; 68(5):669-675. PubMed ID: 30628981
[TBL] [Abstract][Full Text] [Related]
2. The use of serum calprotectin as a biomarker for inflammatory activity in inflammatory bowel disease.
Suárez Ferrer C; Abadía Barno M; Martín Arranz E; Jochems A; García Ramírez L; Poza Cordón J; Jaquotot Herranz M; Cerpa Arencibia A; Martín Arranz MD
Rev Esp Enferm Dig; 2019 Oct; 111(10):744-749. PubMed ID: 31476872
[TBL] [Abstract][Full Text] [Related]
3. Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease.
Samant H; Desai D; Abraham P; Joshi A; Gupta T; Dherai A; Ashavaid T
Indian J Gastroenterol; 2015 Nov; 34(6):431-5. PubMed ID: 26589229
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China.
Chen JM; Liu T; Gao S; Tong XD; Deng FH; Nie B
World J Gastroenterol; 2017 Dec; 23(46):8235-8247. PubMed ID: 29290660
[TBL] [Abstract][Full Text] [Related]
5. Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.
Kalla R; Kennedy NA; Ventham NT; Boyapati RK; Adams AT; Nimmo ER; Visconti MR; Drummond H; Ho GT; Pattenden RJ; Wilson DC; Satsangi J
Am J Gastroenterol; 2016 Dec; 111(12):1796-1805. PubMed ID: 27596694
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Serum Calprotectin Levels in Patients with Inflammatory Bowel Disease.
Mori A; Mitsuyama K; Sakemi R; Yoshioka S; Fukunaga S; Kuwaki K; Yamauchi R; Araki T; Yoshimura T; Yamasaki H; Tsuruta K; Morita T; Yamasaki S; Tsuruta O; Torimura T
Kurume Med J; 2021 Dec; 66(4):209-215. PubMed ID: 34690210
[TBL] [Abstract][Full Text] [Related]
7. Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease.
Hoekman DR; Diederen K; Koot BG; Tabbers MM; Kindermann A; Benninga MA
Eur J Pediatr; 2016 Oct; 175(10):1335-42. PubMed ID: 27573259
[TBL] [Abstract][Full Text] [Related]
8. Fecal calprotectin as a marker of the severity of mucosal inflammation in children with inflammatory bowel disease.
Dolinšek J; Rižnik P; Sabath L; Mičetić-Turk D
Wien Klin Wochenschr; 2016 Apr; 128(7-8):253-9. PubMed ID: 26659704
[TBL] [Abstract][Full Text] [Related]
9. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.
Fukunaga S; Kuwaki K; Mitsuyama K; Takedatsu H; Yoshioka S; Yamasaki H; Yamauchi R; Mori A; Kakuma T; Tsuruta O; Torimura T
Int J Mol Med; 2018 Jan; 41(1):107-118. PubMed ID: 29115397
[TBL] [Abstract][Full Text] [Related]
10. High Percentage of IBD Patients with Indefinite Fecal Calprotectin Levels: Additional Value of a Combination Score.
Bodelier AG; Jonkers D; van den Heuvel T; de Boer E; Hameeteman W; Masclee AA; Pierik MJ
Dig Dis Sci; 2017 Feb; 62(2):465-472. PubMed ID: 27933473
[TBL] [Abstract][Full Text] [Related]
11. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
[TBL] [Abstract][Full Text] [Related]
12. TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
Grimstad T; Skoie IM; Doerner J; Isaksen K; Karlsen L; Aabakken L; Omdal R; Putterman C
Scand J Gastroenterol; 2017 Apr; 52(4):420-424. PubMed ID: 28040992
[TBL] [Abstract][Full Text] [Related]
13. Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease.
Shimoyama T; Yamamoto T; Yoshiyama S; Nishikawa R; Umegae S
Inflamm Bowel Dis; 2023 Sep; 29(9):1399-1408. PubMed ID: 36334015
[TBL] [Abstract][Full Text] [Related]
14. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
15. [Significance of serum calprotectin in assessing inflammatory bowel disease activity].
Mao JY; Li L; Pang Z
Zhonghua Yi Xue Za Zhi; 2017 Oct; 97(38):3001-3004. PubMed ID: 29061007
[No Abstract] [Full Text] [Related]
16. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis.
Lee SH; Kim MJ; Chang K; Song EM; Hwang SW; Park SH; Yang DH; Kim KJ; Byeon JS; Myung SJ; Yang SK; Ye BD
BMC Gastroenterol; 2017 Oct; 17(1):110. PubMed ID: 29061121
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
18. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
[TBL] [Abstract][Full Text] [Related]
19. The Toronto IBD Global Endoscopic Reporting [TIGER] Score: A Single, Easy to Use Endoscopic Score for Both Crohn's Disease and Ulcerative Colitis Patients.
Zittan E; Steinhart AH; Aran H; Milgrom R; Gralnek IM; Zelber-Sagi S; Silverberg MS
J Crohns Colitis; 2022 May; 16(4):544-553. PubMed ID: 34272937
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy.
Engström J; Lönnkvist M; Befrits R; Ljung T; Diaz-Tartera H; Holst M; Hellström PM
Scand J Gastroenterol; 2019 Sep; 54(9):1081-1088. PubMed ID: 31499013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
